{"id":177668,"date":"2021-01-25T12:00:57","date_gmt":"2021-01-25T12:00:57","guid":{"rendered":"https:\/\/www.transcend.org\/tms\/?p=177668"},"modified":"2021-01-21T08:21:55","modified_gmt":"2021-01-21T08:21:55","slug":"cuba-will-produce-100-million-doses-of-its-covid-19-vaccine","status":"publish","type":"post","link":"https:\/\/www.transcend.org\/tms\/2021\/01\/cuba-will-produce-100-million-doses-of-its-covid-19-vaccine\/","title":{"rendered":"Cuba Will Produce 100 Million Doses of Its COVID-19 Vaccine"},"content":{"rendered":"
\n

This year, Cuba will produce 100 million doses of its new Soberana 02 coronavirus vaccine to meet its internal demand and those of other countries, a leading Cuban scientist reported today.<\/em><\/p><\/blockquote>\n

\"\"<\/a>

Cuba to begin clinical trials of COVID-19 vaccine. Anadolu Agency<\/p><\/div>\n

20 Jan 2021 – <\/em>“We are reorganizing our production capacities because we really have a lot of demand for the vaccine and we have to prepare ourselves,” Vicente V\u00e9rez, director of the Finlay Institute, told a group of journalists at a conference in which he gave a tour of the laboratory where the vaccine against COVID-19 is manufactured.<\/p>\n

The Finlay Institute\u00a0has created\u00a0both Soberana 02 and Soberana 01, the latter in a less advanced research phase. Other biotechnology centers on the island are working on two more vaccine candidates,\u00a0Abdala and Mambisa.<\/p>\n

RELATED: Cuba’s Soberana 02 Vaccine Starts Phase II of Clinical Trials<\/a><\/em><\/strong><\/p><\/blockquote>\n

The 100 million doses planned would be only of Soberana\u00a002. There are already countries interested in acquiring it, such as Vietnam, Iran, and Venezuela, among others, with which the island has collaboration agreements, including Pakistan and India,\u00a0V\u00e9rez\u00a0said.<\/p>\n

This week began the second part of a Phase II trial of this product with 900 patients — who joined about a hundred from the first stage — at a polyclinic in the capital; The Associated Press reported the day before.<\/p>\n

The volunteers — one group of whom received a placebo as part of the study, although they will be immunized with the actual vaccine once it is over — said they reported no discomfort. Even some neighbors at the polyclinic came forward to volunteer as part of the trial.<\/p>\n

After being injected, people–ranging in age from 19 to 80 years–waited at the same polyclinic before returning home and were followed up at 24, 48, and 72 hours.<\/p>\n

\n

"Cuba will produce 100 million COVID-19 vaccine doses. BIOCENCU & FinlayInstitute are coordinating the large-scale productive output of Soberana02 for mass vaccination on the island & sharing it with those interested in acquiring it, like India, Vietnam, Iran and Venezuela." https:\/\/t.co\/7L65gc4k0F<\/a><\/p>\n

— teleSUR English (@telesurenglish) January 21, 2021<\/a><\/p><\/blockquote>\n